Liu L, Guo D, Liang Q, Ding S, Wu B, Zhang L, Li Q
Department of Experimental Immunology, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Shanghai, China.
Clin Exp Allergy. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417.
Sublingual immunotherapy (SLIT) is a potential treatment for house dust mite-induced atopic dermatitis (AD). However, the mechanisms of action are not clear.
To establish a mouse model of AD in order to study the effect and mechanisms of SLIT.
Mice were sensitized and subsequently challenged by repeated cutaneous application of Der f allergen extract. Sensitized mice were SLIT-treated with a Der f vaccine and analyzed for AD symptoms, histopathological and immunological parameters. This experiment was carried in the Laboratory Animal Center, Shanghai University of TCM.
Repeated application of Der f extract caused rapid increase in dermatitis scores. Clinical findings (scratching behaviour, dermatitis and oedema) and histological symptoms (inflammatory cell infiltration) in this model were very similar to those in human AD. Serum total and Der f-specific IgE and IgG levels, and the expression level of T helper (Th)2 cytokine IL-5, IL-13; and Th1 cytokine IL-12 and IFN-γ were elevated compared with the control mice. SLIT treatment of sensitized mice markedly reduced the clinical and histopathological symptoms and decreased both Th1 and Th2 cytokine levels.
The mouse model induced by Der f allergen extract reflected the typical hallmarks of human AD. In the Der f allergens-sensitized mice, SLIT treatment with Der f vaccine was shown to significantly inhibit AD symptoms through correction of Th2 and Th1 cytokine predominance. Our study suggested that SLIT could be considered as an attractive treatment for patients with extrinsic AD.
舌下免疫疗法(SLIT)是治疗屋尘螨诱发的特应性皮炎(AD)的一种潜在疗法。然而,其作用机制尚不清楚。
建立AD小鼠模型以研究SLIT的效果及机制。
通过反复经皮应用Der f变应原提取物使小鼠致敏,随后进行激发。对致敏小鼠用Der f疫苗进行SLIT治疗,并分析AD症状、组织病理学和免疫学参数。本实验在上海中医药大学实验动物中心进行。
反复应用Der f提取物导致皮炎评分迅速升高。该模型中的临床表现(搔抓行为、皮炎和水肿)及组织学症状(炎性细胞浸润)与人类AD非常相似。与对照小鼠相比,血清总IgE、Der f特异性IgE和IgG水平,以及辅助性T细胞(Th)2细胞因子IL-5、IL-13;和Th1细胞因子IL-12及IFN-γ的表达水平均升高。对致敏小鼠进行SLIT治疗可显著减轻临床和组织病理学症状,并降低Th1和Th2细胞因子水平。
Der f变应原提取物诱导的小鼠模型反映了人类AD的典型特征。在Der f变应原致敏的小鼠中,用Der f疫苗进行SLIT治疗可通过纠正Th2和Th1细胞因子优势来显著抑制AD症状。我们的研究表明,SLIT可被视为外源性AD患者的一种有吸引力的治疗方法。